Antengene Corporation Limited (6996.HK)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jay Mei M.D., Ph.D. | Founder, Chairman & CEO | 11.27M | -- | 1965 |
| Mr. Donald Andrew Lung J.D., M.B.A. | CFO & Executive Director | 3.34M | -- | 1982 |
| Ms. Rui Guo | Executive Officer | -- | -- | -- |
| Mr. Eitan Liu M.Sc. | Chief Operating Officer | -- | -- | 1985 |
| Ms. Shimin Sun M.D., M.P.H. | Corporate VP and Head of Clinical Enabling Functions & Operational Excellence | -- | -- | -- |
| Mr. Thomas Karalis B.Sc. | Corporate VP & Head of Asia Pacific Region | -- | -- | -- |
| Dr. Dirk Hoenemann | VP and Head of Medical Affairs for APAC & Early Clinical Development | -- | -- | -- |
| Mr. Yang Cao C.F.A. | Joint Company Secretary | -- | -- | -- |
| Mr. Wai Chiu Wong C.P.A., CTP, FCS | Joint Company Secretary | -- | -- | 1956 |
Antengene Corporation Limited
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 169
Description
Antengene Corporation Limited, a biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. Its commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor for the treatment of cervical cancer and other advanced solid tumors. The company also develops other clinical stage assets, such as ATG-022, an antibody-drug conjugate which is in Phase II for the treatment of patients with advanced or metastatic gastric cancer; ATG-031, an anti-CD24 monoclonal antibody, which is in Phase I for the treatment of advanced solid tumors; ATG-037, an CD73 inhibitor that is in Phase I for the treatment of locally advanced or metastatic solid tumors; and ATG-101, a PD-L1/4-1BB bispecific antibody, which is I Phase I trial for the treatment of advanced/metastatic solid tumors and B-cell non Hodgkin lymphoma (B-NHL). In addition, its pre-clinical stage assets consist of ATG-042, an PRMT5-MTA inhibitor; ATG-201 a CD19 x CD3 T cell engager; ATG-102, a LILRB4 x CD3 T cell engager; ATG-106, a CDH6 x CD3 T cell engager; ATG-107, a FLT3 x CD3 T cell engager; and ATG-110, a LY6G6D x CD3 T cell engager. Further, it develops AnTenGager, an 2+1 T cell engager platform which enables conditional T cell activation with reduced risk of cytokine release syndrome; and engages in the trading activities. Antengene Corporation Limited was founded in 2017 and is based in Shanghai, China.
Corporate Governance
Upcoming Events
March 21, 2025 at 10:59 AM UTC
Antengene Corporation Limited Earnings Date
Recent Events
Recent Events Information Not Available